SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Michael Vi/Shutterstock
Business
Jazz’s $375M Investment in Zymeworks Paying Off in GI Cancer
Jazz Pharmaceuticals and Zymeworks announced results from a Phase II trial of the latter’s HER2-targeted antibody for metastatic gastroesophageal adenocarcinoma.
January 19, 2023
 · 
1 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Drug Development
Phase II Terminations Climb as Breast Cancer Remains Most Studied in 2022
Breast cancer came in as the most studied disease in 2022, according to the patient data analytics firm Phesi.
January 18, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Study: Harvard Scientists Pinpoint Epigenetics as Potential Key to Reverse Aging
Harvard scientists believe they’ve uncovered one of the primary drivers of aging, and it isn’t DNA mutation. A study published Thursday points to epigenetics as the key.
January 13, 2023
 · 
3 min read
 · 
Kate Goodwin
Young team during virus lab tests. Multi ethnic scientists focused on work. Wearing protective workwear
Drug Development
BioXcel Spinout Posts Promising Results in Rare Prostate Cancer
BioXcel Therapeutics subsidiary OnkosXcel announced positive Phase II results in patients with small cell neuroendocrine metastatic castration-resistant (SCNC) prostate cancer.
January 11, 2023
 · 
2 min read
 · 
Kate Goodwin
Voyager CEO Al Sandrock/courtesy of Voyager Therap
Business
Second Neurocrine-Voyager Pact Targets Underlying Cause of Parkinson’s (Updated)
Neurocrine Biosciences and Voyager Therapeutics inked a CNS-targeted collaboration potentially worth a potential $4.4 billion.
January 9, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Sarah Silbiger/Getty Images
Drug Development
NeoCart’s Revival Continues as FDA Approves Ocugen’s Phase III Trial Design (Updated)
Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.
December 16, 2022
 · 
3 min read
 · 
Kate Goodwin
Michel Stoupak/NurPhoto via Getty Images
Business
First Protein Degrader Tested Outside Oncology Yields Promising Results
Kymera and Sanofi shared positive results for an IRAK4 degrader for hidradenitis suppurativa and atopic dermatitis.
December 14, 2022
 · 
1 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Drug Development
Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris
Seagen’s top-selling drug hit the mark in another major indication.
December 12, 2022
 · 
1 min read
 · 
Kate Goodwin
Doctor dermatologist examining birthmarks and moles on a female patient's hand. Close up cropped image of examination of birthmarks with modern device, using light and phone application and camera
Drug Development
UCB Reports Positive Pivotal for New Approach to Hidradenitis Suppurativa (Updated)
UCB shared positive top-line results Friday from two Phase III studies of bimekizumab for adults with moderate to severe hidradenitis suppurativa.
December 9, 2022
 · 
2 min read
 · 
Kate Goodwin
Shutterstock
Drug Development
Neurocrine’s $50M Neuro Asset Takes Strike Two
Neurocrine’s NBI-827104 failed to meet the primary endpoint in a Phase II study for epileptic encephalopathy with continuous spike-and-wave during sleep, the company announced Tuesday.
December 7, 2022
 · 
2 min read
 · 
Kate Goodwin
Terazosin shows top line results in ALS treatment.
Drug Development
CTAD: TauRx Touts Safety Profile as Anavex Stumbles over Data Discrepency (Updated)
TauRx Pharmaceuticals and Anavex Life Sciences presented positive results from their candidates at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Francisco, CA.
December 2, 2022
 · 
3 min read
 · 
Kate Goodwin
Paula Ragan, X4 President and CEO/Company Courtesy
Drug Development
After a Tough Summer, X4 Celebrates Phase III Win in WHIM Syndrome (Updated)
Four months after implementing a restructuring initiative to extend cash flow, X4 Pharmaceuticals is celebrating positive top-line results in WHIM syndrome.
November 30, 2022
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Nectin’s Series A Hits $25M as Investors Support New Target for Solid Tumors
Nectin Therapeutics announced dosing of the first solid tumor patient in a Phase I clinical trial while additional investors jumped in to expand the company’s Series A to just over $25 million.
November 30, 2022
 · 
3 min read
 · 
Kate Goodwin
Business
Spectrum Cuts NSCLC Program and 75% of Staff on Heels of CRL
Spectrum Pharmaceuticals made the call Friday to slash three-fourths of its workforce on the heels of a Complete Response Letter from the FDA.
November 28, 2022
 · 
1 min read
 · 
Kate Goodwin
lucarista/Shutterstock
Business
Novartis and MMV Move to Pivotal Study with New Class of Drug for Malaria
Novartis and Medicines for Malaria Venture are moving into Phase III for a combination treatment targeting the rise of artemisinin-resistant Malaria infection.
November 23, 2022
 · 
3 min read
 · 
Kate Goodwin
Load More